165 related articles for article (PubMed ID: 20392862)
1. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.
Farlow MR; Cummings JL; Olin JT; Meng X
Am J Alzheimers Dis Other Demen; 2010 Jun; 25(4):347-52. PubMed ID: 20392862
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
[TBL] [Abstract][Full Text] [Related]
3. Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.
Grossberg GT; Schmitt FA; Meng X; Tekin S; Olin J
Am J Alzheimers Dis Other Demen; 2010 Dec; 25(8):627-33. PubMed ID: 21131668
[TBL] [Abstract][Full Text] [Related]
4. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
5. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.
Weintraub D; Somogyi M; Meng X
Am J Alzheimers Dis Other Demen; 2011 Sep; 26(6):443-9. PubMed ID: 22009228
[TBL] [Abstract][Full Text] [Related]
6. Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items.
Schmitt FA; Aarsland D; Brønnick KS; Meng X; Tekin S; Olin JT
Am J Alzheimers Dis Other Demen; 2010 Aug; 25(5):407-13. PubMed ID: 20392860
[TBL] [Abstract][Full Text] [Related]
7. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
8. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
9. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
10. Rivastigmine for Alzheimer's disease.
Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
[TBL] [Abstract][Full Text] [Related]
11. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
12. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial.
Mowla A; Mosavinasab M; Haghshenas H; Borhani Haghighi A
J Clin Psychopharmacol; 2007 Oct; 27(5):484-7. PubMed ID: 17873681
[TBL] [Abstract][Full Text] [Related]
13. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Battle CE; Abdul-Rahim AH; Shenkin SD; Hewitt J; Quinn TJ
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013306. PubMed ID: 33704781
[TBL] [Abstract][Full Text] [Related]
14. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
[TBL] [Abstract][Full Text] [Related]
15. Rivastigmine for Alzheimer's disease.
Birks JS; Grimley Evans J
Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
[TBL] [Abstract][Full Text] [Related]
16. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine for Alzheimer's disease.
Birks J; Grimley Evans J ; Iakovidou V; Tsolaki M
Cochrane Database Syst Rev; 2000; (4):CD001191. PubMed ID: 11034705
[TBL] [Abstract][Full Text] [Related]
18. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations.
Cummings J; Emre M; Aarsland D; Tekin S; Dronamraju N; Lane R
J Alzheimers Dis; 2010; 20(1):301-11. PubMed ID: 20164585
[TBL] [Abstract][Full Text] [Related]
19. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
[TBL] [Abstract][Full Text] [Related]
20. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study.
Saumier D; Duong A; Haine D; Garceau D; Sampalis J
J Nutr Health Aging; 2009 Nov; 13(9):808-12. PubMed ID: 19812871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
